Trump Nominates Surgeon Dr. Marty Makary as FDA Commissioner, Says He Will 'Course-Correct' the Agency

Nov.25.2024
Trump Nominates Surgeon Dr. Marty Makary as FDA Commissioner, Says He Will 'Course-Correct' the Agency
Trump nominates Johns Hopkins surgical oncologist and health policy expert Dr. Marty Makary for FDA Commissioner. Trump stated that FDA has lost sight of its primary regulatory goals. Dr. Makary, with his outstanding contributions to healthcare transparency and public health, will help refocus the agency and restore public trust.

President-elect Donald Trump recently announced on the social media platform Truth Social that he intends to nominate Dr. Martin Makary, a renowned pancreatic surgeon from Johns Hopkins University, as the Commissioner of FDA.

 

Trump Nominates Surgeon Dr. Marty Makary as FDA Commissioner, Says He Will 'Course-Correct' the Agency
Original statement | Image source: Truth Social

 

In his statement, Trump said, "FDA has lost the trust of Americans and has lost sight of its primary goal as a regulator. The Agency needs Dr. Marty Makary, a Highly Respected Johns Hopkins Surgical Oncologist and Health Policy Expert, to course-correct and refocus the Agency."

 

Trump Nominates Surgeon Dr. Marty Makary as FDA Commissioner, Says He Will 'Course-Correct' the Agency
Introduction on Johns Hopkins Hospital | Image source: Johns Hopkins University

 

 

About Dr. Marty Makary, according to the Johns Hopkins University website:

 

Dr. Marty Makary is a surgeon and public policy researcher at Johns Hopkins University. He writes for The Washington Post and The Wall Street Journal and is the author of two New York Times bestselling books, Unaccountable and The Price We Pay. Dr. Makary served in leadership at the World Health Organization Patient Safety Program and has been elected to the National Academy of Medicine.

 

Clinically, Dr. Makary is the chief of Islet Transplant Surgery at Johns Hopkins. He is the recipient of the Nobility in Science Award from the National Pancreas Foundation and has been a visiting professor at over 25 medical schools. He has published over 250 peer-reviewed scientific articles and has served on several editorial boards.

 

Dr. Makary is the recipient of the 2020 Business Book of the Year Award by the Association of Business Journalists for his most recent book, The Price We Pay. It has been described by Don Berwick as "a deep dive into the real issues driving up the price of health care" and by Steve Forbes as "A must-read for every American".

 

Dr. Makary serves as a professor at the Johns Hopkins School of Medicine and a professor, by courtesy, at the Johns Hopkins Carey Business School. His current research focuses on the underlying causes of disease, public policy, health care costs, and relationship-based medicine.

 

Cover image source: New York Times.

 

British American Tobacco France Survey: Nearly 70% Back Nicotine Pouch Sales
British American Tobacco France Survey: Nearly 70% Back Nicotine Pouch Sales
According to a commissioned survey by British American Tobacco France, consumer awareness of nicotine pouches in France remains low, particularly among older demographics, with 39% of respondents saying they were unfamiliar with the product. While a majority supports stricter regulation — including higher fines and the introduction of licensing systems — 68% believe adults should be allowed to purchase nicotine pouches. Meanwhile, 86% agree that sales to minors should be prohibited.
Apr.27 by 2FIRSTS.ai
Swedish Study: Nicotine Pouches Help Boost Smoking Cessation Among Women by 200%, Advancing Smoke-Free Goals
Swedish Study: Nicotine Pouches Help Boost Smoking Cessation Among Women by 200%, Advancing Smoke-Free Goals
A Swedish study finds that since 2016, oral nicotine pouches have helped cut smoking rates, with women quitting nearly 200% more. Sweden’s smoking rate is now 5.3%, close to the smoke-free target of 5%. Experts say nicotine pouches are safe, easy, and effective for quitting.
Jun.19 by 2FIRSTS.ai
2Firsts Interviews ITGA President Jose Aranda: Defending Growers’ Interests Amid the Rise of Next-Generation Products
2Firsts Interviews ITGA President Jose Aranda: Defending Growers’ Interests Amid the Rise of Next-Generation Products
As next-generation products reshape the global tobacco landscape, ITGA President Jose Aranda tells 2Firsts that growers must be included in policymaking, not sidelined. He advocates for stronger international cooperation to help farmers adapt to sustainability, climate, and market challenges.
Jun.05
Controversy over Terengganu vape ban in Malaysia: Association challenges legality and urges postponement
Controversy over Terengganu vape ban in Malaysia: Association challenges legality and urges postponement
Terengganu, Malaysia will implement a vape sales ban starting August 1, raising concerns from the Terengganu branch of the Malaysia Vape Chamber of Commerce, which warned the move could cause traders losses of up to USD 1.15 million per month and questioned the legality of the ban.
Apr.28 by 2FIRSTS.ai
Firstunion Launches World’s First Puff-to-Heat Product, PTH MASTER, Ushering in a New Era of Heated Tobacco
Firstunion Launches World’s First Puff-to-Heat Product, PTH MASTER, Ushering in a New Era of Heated Tobacco
On May 30, Firstunion Group globally launched the PTH MASTER, the world’s first puff-to-heat heated tobacco device. Featuring three major technological breakthroughs, it eliminates pre-heating delays and flavor inconsistencies while enabling instant activation, precise control, and on-demand pausing—ushering in a new era of heated tobacco.
Jun.05
Itsuwa Posts 194% Drop in 2024 Net Profit with $2.7M Loss, to Focus on Modular and Eco-Friendly E-Cigarettes
Itsuwa Posts 194% Drop in 2024 Net Profit with $2.7M Loss, to Focus on Modular and Eco-Friendly E-Cigarettes
Itsuwa Technology (NEEQ: 833767) released its 2024 annual report, reporting revenue of 283 million yuan, down 12.59% year-on-year, and a net loss of 19.66 million yuan, a 194.47% decline from the previous year. The company attributed the loss to intense competition and product homogeneity in overseas markets, as well as rising labor costs. Its gross profit margin dropped to 30%, while R&D spending accounted for 9.12% of revenue. Going forward, the company plans to focus on developing eco-friendl
May.13 by 2FIRSTS.ai